Chapter 8 - the file called H-07
The H-07 folder was incomplete.
Several pages were missing.
But the remaining records established a timeline.
Cycle One:
Routine assessments.
Cycle Two:
Repeated administration of an unidentified research compound.
Cycle Three:
Monitoring after exposure.
Dr. Morris refused to speculate publicly about the exact substance until laboratory analysis was complete.
What mattered immediately was simple:
Lila had received something medically active.
Repeatedly.
Without legitimate oversight.
And her condition suggested she had not tolerated it well.
One note from Martin Vale read:
H-07 fatigue significant. Continue if paternal consent remains.
Another:
Maternal interference risk contained.
Nora stared at those four words.
Contained.
That was how her removal from her daughter’s life had been described.
Not custody.
Not family conflict.
A research obstacle contained.
Detective Cole obtained search warrants for Vale’s hospital office.
Inside one locked drawer:
Blank informed-consent forms.
Copies of children’s school health summaries.
A BrightPath budget.
Payments routed through Children Forward Foundation.
And a list.
PHASE II CANDIDATES.
Twenty-three initials.
H-07 included.
Lila was one of twenty-three children being considered.
The hospital chief executive held a press conference.
St. Matthew denied authorizing BrightPath.
Vale had apparently used his title and access to give the program credibility without formal institutional approval.
The hospital opened an independent review.
Families began calling investigators.
One mother recognized Aaron Voss from a photograph.
Her nine-year-old son had attended “immune resilience evaluations.”
Another parent said Dean Harper told them the program was connected to St. Matthew.
Vale’s hospital position had been the sales pitch.
Police located Aaron Voss three days later at a rented house in Maryland.
He surrendered through counsel.
His attorney insisted Voss believed the program was scientifically justified.
Detective Cole cared about documentation.
Where were the complete files?
Where were the compounds sourced?
Who funded the national study?
Voss refused to answer.
Then investigators recovered a laptop from Dean’s warehouse.
Deleted files were partially restored.
One spreadsheet listed sponsor payments.
Most came from shell nonprofits.
One came from a corporation:
Asterion Biologics.
Dr. Morris knew the name.
A small private biotechnology company based in Boston.
It developed early-stage immune-modulation research.
Asterion denied authorizing pediatric use outside approved studies.
The company said no active clinical trial involved Lila Harper.
So why did BrightPath have Asterion-labeled internal references?
Counterfeit?
Stolen material?
Unauthorized research?
Nobody knew yet.
Then the hospital lab identified the general compound class in Lila’s blood.
It was consistent with an experimental immune-modulating formulation.
Not a vitamin.
Not routine pediatric care.
Dr. Morris told Nora carefully:
“We still do not know exactly what formulation was used or at what concentration.”
“Can she recover?”
“We are treating what we see. Right now she is improving.”
Nora looked toward Lila sleeping.
“That’s all I need today.”
Lila’s strength slowly returned.
She could sit without dizziness.
Eat.
Walk a few careful steps.
But she asked every morning:
“Is it Wednesday?”
Even after Wednesday passed.
Trauma did not care about calendars.
Ms. Kincaid visited with a card signed by the class.
No on-screen text mattered only to the video; in story, paper is fine.
Mason drew a cat.
Another child drew Lila’s desk with stars around it.
Ms. Kincaid handed Lila the pale blue cardigan.
“It was still in the nurse’s office.”
Lila hugged it.
Then something fell from the pocket.
A small laminated visitor badge.
BrightPath Children Forward Foundation.
Date:
Six weeks earlier.
Lila stared.
“Daddy told me to throw that away.”
Nora looked toward Detective Cole.
The badge included a QR-style registration number.
Hospital investigators traced it.
The number connected to a hidden participant portal.
H-07.
And beside Lila’s name:
ENROLLMENT ORIGIN — SCHOOL HEALTH REFERRAL.
Ms. Kincaid froze.
“The school never referred her.”
Nurse Dana agreed.
Neither had.
Somebody had falsely represented the elementary school as the source of Lila’s enrollment.
The portal listed the referring professional.
D. REEVES.
Dana Reeves.
The school nurse.
Dana stared.
“I never signed anything.”
Now her identity had been used too.
The forgery extended beyond Nora.
Someone had built paperwork making BrightPath look legitimate from every direction.
Parent.
School.
Hospital.
May you like
Each institution apparently approving what the others never knew about.
👉 BrightPath had forged the school nurse’s referral as well as Nora’s consent, revealing a deliberate system designed to make every adult believe someone else had already approved the treatments.
